Courier Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 2

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $510M

  • Investors
  • 1

Courier Therapeutics General Information

Description

Developer of a therapy platform designed for precise delivery of cytokines to NK and CD8 T cells. The company's technology is based on observations about viral stealth proteins that have evolved over millions of years to target certain receptors with affinity to eliminate target effects of cytokine therapy while increasing efficacy, enabling organizations to activate the immune systems to fight cancer.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 3737 Buffalo Speedway
  • Suite 1750
  • Houston, TX 77098
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 3737 Buffalo Speedway
  • Suite 1750
  • Houston, TX 77098
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Courier Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 28-May-2021 $510M Completed Pre-Clinical Trials
5. Early Stage VC 13-Aug-2018 Completed Startup
4. Grant 01-Jan-2018 Completed Startup
3. Seed Round 03-Oct-2016 Completed Startup
2. Accelerator/Incubator 01-Aug-2016 Completed Startup
1. University Spin-Out 01-Jan-2015 Completed Startup
To view Courier Therapeutics’s complete valuation and funding history, request access »

Courier Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed
To view Courier Therapeutics’s complete cap table history, request access »

Courier Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a therapy platform designed for precise delivery of cytokines to NK and CD8 T cells. The company's technolo
Drug Discovery
Houston, TX
2 As of 2022

Schlieren, Switzerland
 

New Haven, CT
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Courier Therapeutics Competitors (78)

One of Courier Therapeutics’s 78 competitors is ImmunOs Therapeutics, a Venture Capital-Backed company based in Schlieren, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ImmunOs Therapeutics Venture Capital-Backed Schlieren, Switzerland
Arvinas Formerly VC-backed New Haven, CT
Exo Therapeutics Venture Capital-Backed Cambridge, MA
RootPath Venture Capital-Backed Framingham, MA
Plexium Venture Capital-Backed San Diego, CA
You’re viewing 5 of 78 competitors. Get the full list »

Courier Therapeutics Patents

Courier Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2021030588-A1 Orthopoxvirus major histocompatibility complex (mhc) class-i like protein (omcp) for treatment of autoimmune disease Inactive 13-Aug-2019
GB-202112934-D0 Bispecific fusion protein using orthopoxvirus major histocompatibility complex (mhc) class 1-like protein (omcp) and tumor-specific binding partner Active 18-Feb-2019
GB-2596001-A Bispecific fusion protein using orthopoxvirus major histocompatibility complex (mhc) class 1-like protein (omcp) and tumor-specific binding partner Active 18-Feb-2019
GB-2596001-A8 Bispecific fusion protein using orthopoxvirus major histocompatibility complex (mhc) class 1-like protein (omcp) and tumor-specific binding partner Active 18-Feb-2019
CA-3130582-A1 Bispecific fusion protein using orthopoxvirus major histocompatibility complex (mhc) class i-like protein (omcp) and tumor-specific binding partner Pending 18-Feb-2019 C07K14/005
To view Courier Therapeutics’s complete patent history, request access »

Courier Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Courier Therapeutics Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
BioGenerator Ventures Venture Capital Minority
Johnson & Johnson Innovation - JLABS Accelerator/Incubator
Mercury Fund Venture Capital Minority
U.S. Department of Health and Human Services Government
To view Courier Therapeutics’s complete investors history, request access »

Courier Therapeutics FAQs

  • When was Courier Therapeutics founded?

    Courier Therapeutics was founded in 2015.

  • Where is Courier Therapeutics headquartered?

    Courier Therapeutics is headquartered in Houston, TX.

  • What is the size of Courier Therapeutics?

    Courier Therapeutics has 2 total employees.

  • What industry is Courier Therapeutics in?

    Courier Therapeutics’s primary industry is Drug Discovery.

  • Is Courier Therapeutics a private or public company?

    Courier Therapeutics is a Private company.

  • What is the current valuation of Courier Therapeutics?

    The current valuation of Courier Therapeutics is .

  • What is Courier Therapeutics’s current revenue?

    The current revenue for Courier Therapeutics is .

  • How much funding has Courier Therapeutics raised over time?

    Courier Therapeutics has raised $460K.

  • Who are Courier Therapeutics’s investors?

    BioGenerator Ventures, Johnson & Johnson Innovation - JLABS, Mercury Fund, and U.S. Department of Health and Human Services have invested in Courier Therapeutics.

  • Who are Courier Therapeutics’s competitors?

    ImmunOs Therapeutics, Arvinas, Exo Therapeutics, RootPath, and Plexium are some of the 78 competitors of Courier Therapeutics.

  • When was Courier Therapeutics acquired?

    Courier Therapeutics was acquired on 28-May-2021.

  • Who acquired Courier Therapeutics?

    Courier Therapeutics was acquired by Valo.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process